Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AB 1001 - BrainVectis

Next Previous
Drug Profile

AB 1001 - BrainVectis

Alternative Names: AAV-CYP46A1; AAV-mediated CYP46A1 gene therapy - BrainVectis; AAVrh10.CAG.hCYP46A1; AB-1001 - BrainVectis; BV-101; BV-CYP01; Huntington's Disease rAAV Gene Therapy - Bayer; rAAVrh10.CYP46A1wt

Latest Information Update: 25 Oct 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BrainVectis
  • Class Antidementias; Gene therapies
  • Mechanism of Action Cholesterol 24 hydroxylase replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Huntington's disease
  • Discontinued Alzheimer's disease; Spinocerebellar degeneration

Most Recent Events

  • 10 Oct 2022 Phase-I/II clinical trials in Huntington's disease in France (Intracerebral)
  • 27 Sep 2022 BV 101 is still in preclinical development phase for Huntington's disease in France
  • 28 Aug 2022 No recent reports of development identified for preclinical development in Huntington's-disease in France (Intracerebral, Injection)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top